UK MHRA 'Could Set Up Standalone System' But Faces Post-Brexit Loss Of Income & Influence
Executive Summary
The UK regulator is realistic about the threats Brexit poses to its income and influence, but is confident it can set up a standalone regulatory system and has some ideas for working with the European Medicines Agency under the future relationship between the UK and the EU.
You may also be interested in...
UK And EMA Could Work Together Informally After Brexit
The UK may not be able to participate in the European Medicines Agency after Brexit, but there are plenty of precedents for informal collaboration among regulatory agencies worldwide. A former European Medicines Agency executive director and legal experts talk to the Pink Sheet about what might be possible.
Brexit: New Rules Will Hit Parallel Trade From UK to EU
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Radical Shake-Up In Store For Entire EU Pharma Legislation
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: